Regenerative medicine for Parkinson's disease

Neurologia Medico-chirurgica
Takao YasuharaIsao Date

Abstract

Regenerative medicine for Parkinson's disease (PD) is expected to develop dramatically with the advancement of biotechnology as represented by induced pluripotent stem cells. Existing therapeutic strategy for PD consists of medication using L-DOPA, surgery such as deep brain stimulation and rehabilitation. Current treatment cannot stop the progression of the disease, although there is definite therapeutic effect. True neurorestoration is strongly desired by regenerative medicine. This review article describes the historical development of regenerative medicine for PD, with a focus on fetal nigral cell transplantation and glial cell line-derived neurotrophic factor infusion. Subsequently, the current status of regenerative medicine for PD in terms of cell therapy and gene therapy are reviewed. In the end, the future direction to realize regenerative medicine for PD is discussed.

References

May 13, 1999·Lancet·C V BorlonganT B Freeman
Mar 10, 2001·The New England Journal of Medicine·C R FreedS Fahn
Oct 29, 2002·Annals of Neurology·Yilong MaDavid Eidelberg
Jan 15, 2003·Neurology·J G NuttUNKNOWN ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor
May 6, 2003·Annals of Neurology·Jerrold L VitekMahlon R DeLong
Sep 4, 2003·Annals of Neurology·C Warren OlanowThomas B Freeman
Jan 5, 2005·The Journal of Clinical Investigation·Yasushi TakagiNobuo Hashimoto
Dec 1, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Takao YasuharaCesario V Borlongan
Jan 16, 2007·Journal of Neurology, Neurosurgery, and Psychiatry·Adolfo Mínguez-CastellanosJosé López-Barneo
Dec 7, 1990·Science·O LindvallA Björklund
Oct 2, 2007·Experimental Neurology·Grégory Porras, Erwan Bezard
Nov 22, 2007·Experimental Neurology·Ayse UlusoyDeniz Kirik
Dec 7, 2007·Nature Biotechnology·Masato NakagawaShinya Yamanaka
Jan 5, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Thomas Gasser
Feb 19, 2008·The FEBS Journal·Andrea C Belin, Marie Westerlund
Oct 11, 2008·Science·Keisuke OkitaShinya Yamanaka
Feb 11, 2009·Cell·Jeong Beom KimHans R Schöler
Apr 29, 2009·Cell Stem Cell·Hongyan ZhouSheng Ding
Nov 11, 2009·Brain Research·Naoki TajiriIsao Date
Jan 7, 2010·The Journal of Clinical Investigation·Evangelos Kiskinis, Kevin Eggan
Jan 29, 2010·Nature·Thomas VierbuchenMarius Wernig
Apr 7, 2010·Science Translational Medicine·Béchir JarrayaStéphane Palfi
Jan 1, 2009·Journal of Neural Transmission. Supplementum·Takao Yasuhara, Isao Date

❮ Previous
Next ❯

Citations

Oct 16, 2015·Neurologia Medico-chirurgica·Anand Tekriwal, Gordon Baltuch
Nov 9, 2017·Cell Transplantation·Takao YasuharaIsao Date

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.